Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Feb;15(1):6-12.
doi: 10.1038/tpj.2014.51. Epub 2014 Oct 7.

An Evaluation of Regulatory and Commercial Barriers to Stratified Medicine Development and Adoption

Affiliations
Review

An Evaluation of Regulatory and Commercial Barriers to Stratified Medicine Development and Adoption

N A Meadows et al. Pharmacogenomics J. .

Abstract

Today, a range of products based on genomics, proteomics and metabolomics have facilitated the development of 'stratified' medicines and companion diagnostics. This investigation profiles a series of targeted medicines and corresponding diagnostics, and their role(s) in supporting evidence-based medicine. Despite their potential benefits we found that scientific, financial and regulatory barriers impede the development and adoption of companion diagnostics. Therefore, in order to realise improvements to the risk/benefit profiles of health-care interventions-notably reducing clinical uncertainty-conferred by the use of companion diagnostics, industry representatives, health-care providers and regulators will need a coordinated response to overcome these barriers.

Similar articles

See all similar articles

Cited by 3 articles

References

    1. N Biotechnol. 2012 Sep 15;29(6):695-708 - PubMed
    1. Pharmacogenomics. 2012 Apr;13(5):571-8 - PubMed
    1. Neuro Oncol. 2013 Aug;15(8):972-8 - PubMed
    1. Eur Heart J. 2011 Jul;32(13):1673-86 - PubMed
    1. Sci Transl Med. 2013 Jul 31;5(196):196cm6 - PubMed

Publication types

MeSH terms

LinkOut - more resources

Feedback